Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Syndecan-2 Surface Expression Identifies Hematopoietic Stem Cells with Increased Repopulating Capacity

Christina Termini, PhDBS, Michelle Li, Joyce Kim, Liman Zhao, John P Chute, MD

Blood (2018) 132 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2018-99-110701

Published: 2018

Journal Articles

Osteoactivin Mediates the Inhibitory Effects of Myeloid Derived Suppressor Cells

Stefanie Andrea Erika Held, PhD, Annkristin Heine, MD, Solveig Daecke, Anita Bringmann, Peter Brossart, MD

Blood (2014) 124 (21): 2745.

https://doi.org/10.1182/blood.V124.21.2745.2745

Published: 2014

Journal Articles

BCR-ABL Tyrosine Kinase Inhibitors Interfere with the PI3K/Akt Signalling Pathway and Activate the Microphthalmia-Associated Transcription Factor (MITF) in Human Dendritic Cells

Daniela Doerfel, MD, Michael Gutknecht, Melanie Märklin, Lothar Kanz, MD, Helmut R. Salih, MD, Frank Gruenebach, Martin R Müller, MD PhD, Susanne M Rittig, MD

Blood (2014) 124 (21): 1416.

https://doi.org/10.1182/blood.V124.21.1416.1416

Published: 2014

Journal Articles

The Use Of Selected Parameters Of Bone Microenvironment For The Assessment Of Skeletal Involvement and Activity In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance

Jiri Minarik, MD, PhD, Petra Pusciznova, MD, Pavla Petrova, MD, Miroslav Herman, prof. MD, Ph.D., Tomas Pika, MD, PhD, Jan Hrbek, MD, Jaroslav Bacovsky, MD, Ph.D., Jana Zapletalova, Vlastimil Scudla, Prof. MD, Ph.D.

Blood (2013) 122 (21): 5339.

https://doi.org/10.1182/blood.V122.21.5339.5339

Published: 2013

Journal Articles

Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma

Sikander Ailawadhi, M.D., Howard A Liebman, MD, Susan Groshen, PhD, Denice D. Tsao-Wei, PhD, Leanne Rochanda, MS, Ibrahim Aldoss, MD, Casey O'Connell, MD, Teresa Wang, Christine Duran, Frederick Rickles, MD, FACP

Blood (2013) 122 (21): 5350.

https://doi.org/10.1182/blood.V122.21.5350.5350

Published: 2013

Journal Articles

Generation of Immunosuppressive Antigen Presenting Cells with the Phenotype and Function of Myeloid Derived Suppressor Cells

Stefanie AE Held, Annkristin Heine, MD, Julia Wolf, Solveig Daecke, Anita Bringmann, PhD, Peter Brossart, MD

Blood (2012) 120 (21): 1032.

https://doi.org/10.1182/blood.V120.21.1032.1032

Published: 2012

Journal Articles

Inhibition of PI3K/Akt and Erk Signaling Pathways by BCR-ABL Tyrosine Kinase Inhibitors up-Regulates the Immunosuppressive Receptor Osteoactivin in Monocyte-Derived Dendritic Cells

Michael Gutknecht, Simone Joas, Lothar Kanz, MD, Helmut R Salih, MD, Susanne M Rittig, MD, Frank Gruenebach, PhD

Blood (2012) 120 (21): 1050.

https://doi.org/10.1182/blood.V120.21.1050.1050

Published: 2012

Journal Articles

Immunosuppressive Drugs up-Regulate the Immunoinhibitory Receptor Osteoactivin On Human Monocyte-Derived Dendritic Cells

Sabine Braun, Michael Gutknecht, Mark-Alexander Schwarzbich, MD, Lothar Kanz, MD, Helmut R Salih, MD, Frank Grünebach, PD, Susanne M Rittig, MD

Blood (2012) 120 (21): 3284.

https://doi.org/10.1182/blood.V120.21.3284.3284

Published: 2012

Journal Articles

Immunosuppressive Drugs Upregulate the Immunoinhibitory Receptor Osteoactivin in Monocyte-Derived Dendritic Cells,

Mark-Alexander Schwarzbich, MD, Michael Gutknecht, Lisa Guettler, Lothar Kanz, MD, Helmut R. Salih, MD, Frank Gruenebach, PhD, Susanne Malaika Rittig, MD

Blood (2011) 118 (21): 3232.

https://doi.org/10.1182/blood.V118.21.3232.3232

Published: 2011

Journal Articles

Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells

Michael Gutknecht, Lisa Güttler, Mark-Alexander Schwarzbich, MD, Julia Salih, Lothar Kanz, MD, Helmut R. Salih, MD, Susanne Malaika Rittig, MD, Frank Grünebach, PD

Blood (2011) 118 (21): 1112.

https://doi.org/10.1182/blood.V118.21.1112.1112

Published: 2011

Journal Articles

Quantitative Proteomic Profiling Unravels Dynamic Changes in the Myeloma Cell Proteome Treated with Valproic Acid (VPA)

P.S. Sasikala, PhD, C. H. Harsha, Ph.D, Jeevisha Bajaj, Rakesh Sharma, Akhilesh Pandey, MD, PhD, Sudhir Krishna, MD, Ph.D

Blood (2011) 118 (21): 1847.

https://doi.org/10.1182/blood.V118.21.1847.1847

Published: 2011

Journal Articles

Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-β on the cell surface

Jin-Sung Chung, Lisa H. Shiue, Madeleine Duvic, Amit Pandya, Ponciano D. Cruz, Jr, Kiyoshi Ariizumi

Blood (2011) 117 (12): 3382–3390.

https://doi.org/10.1182/blood-2010-08-302034

Published: 2011

Includes: Supplemental data

Journal Articles

Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma

Lia Perez, MD, Kelly Boucher, BA, Nancy Parquet, BS, Melissa Alsina, MD, Rachid Baz, MD, Claudio Anasetti, MD, William S. Dalton, PhD, MD

Blood (2010) 116 (21): 1921.

https://doi.org/10.1182/blood.V116.21.1921.1921

Published: 2010

Journal Articles

The Immune-Inhibitory Receptor Osteoactivin Is up-Regulated In Monocyte-Derived Dendritic Cells Upon Exposure to Tyrosine Kinase Inhibitors

Michael Gutknecht, Mark-Alexander Schwarzbich, Julia Salih, Lothar Kanz, MD, Helmut R. Salih, MD, Susanne M. Schmidt, Frank Grünebach

Blood (2010) 116 (21): 1733.

https://doi.org/10.1182/blood.V116.21.1733.1733

Published: 2010

Journal Articles

Mutual Activation and Expansion of Donor CD4 + T Cells and B Cells in Transplants Play a Critical Role in the Initiation of Chronic Graft-Versus-Host Disease.

James Sundblom Young, Dongchang Zhao, Tangsheng Yi, Hongjun Liu, Defu Zeng, MD, PhD

Blood (2009) 114 (22): 1342.

https://doi.org/10.1182/blood.V114.22.1342.1342

Published: 2009

Journal Articles

Integrin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.

Paola Neri, M.D., Li Ren, Ph.D., Kathy Gratton, Alex Klimowicz, Ph.D., Adnan Mansoor, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J Bahlis, MD

Blood (2009) 114 (22): 949.

https://doi.org/10.1182/blood.V114.22.949.949

Published: 2009

Journal Articles

Increased Immunohistochemical CD138 Expression in Waldenström's Macroglobulinemia (WM) in Comparison with Splenic Marginal Zone Lymphoma (SMZL).

Tatiana K Tzenou, G.A. Pangalis, Georgia Levidou, Christina Kalpadakis, Spyros Siakavellas, Dimitrios Maltezas, Efstathios Koulieris, Maria Dimou, Vasiliki Bartzi, Georgios Georgiou, Theodoros P. Vassilakopoulos, Maria K. Angelopoulou, Styliani Kokkoris, Penelope Korkolopoulou, Athina Androulaki, Eystathios Patsouris, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis

Blood (2009) 114 (22): 5008.

https://doi.org/10.1182/blood.V114.22.5008.5008

Published: 2009

Journal Articles

Binding of TACI and APRIL to Syndecan-1 Confer on Them a Major Role in Multiple Myeloma.

Jerome Moreaux, PhD, Anne-Catherine Sprynski, Karene Mahtouk, PhD, Philippe Moine, Nicolas Robert, Jean-François Rossi, MD, PhD, Bernard Klein, PhD

Blood (2007) 110 (11): 3522.

https://doi.org/10.1182/blood.V110.11.3522.3522

Published: 2007

Journal Articles

BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.

Samir Parekh, MD, Jose Polo, MSc, Przemyslaw Juszczynski, MD, PhD, Paola Lev, PhD, Stella Ranuncolo, MD, PhD, Georgio Cattoretti, MD, Rita Shaknovich, MD, Margaret Shipp, MD, Ari Melnick, MD

Blood (2006) 108 (11): 225.

https://doi.org/10.1182/blood.V108.11.225.225

Published: 2006

Journal Articles

Pleiotrophin Promotes Myeloma Proliferation through the Activation of Known and Novel Receptors.

Melinda S. Gordon, PhD, Hee Jin Lee, Richard A. Campbell, Charles B. Drucker, Matthew Katz, Richard K. Leuchter, Benjamin Bonavida, Ph.D., James R. Berenson, M.D.

Blood (2006) 108 (11): 4354.

https://doi.org/10.1182/blood.V108.11.4354.4354

Published: 2006

NARROW

Syndecan-2 Surface Expression Identifies Hematopoietic Stem Cells with Increased Repopulating Capacity

Osteoactivin Mediates the Inhibitory Effects of Myeloid Derived Suppressor Cells

BCR-ABL Tyrosine Kinase Inhibitors Interfere with the PI3K/Akt Signalling Pathway and Activate the Microphthalmia-Associated Transcription Factor (MITF) in Human Dendritic Cells

The Use Of Selected Parameters Of Bone Microenvironment For The Assessment Of Skeletal Involvement and Activity In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance

Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma

Generation of Immunosuppressive Antigen Presenting Cells with the Phenotype and Function of Myeloid Derived Suppressor Cells

Inhibition of PI3K/Akt and Erk Signaling Pathways by BCR-ABL Tyrosine Kinase Inhibitors up-Regulates the Immunosuppressive Receptor Osteoactivin in Monocyte-Derived Dendritic Cells

Immunosuppressive Drugs up-Regulate the Immunoinhibitory Receptor Osteoactivin On Human Monocyte-Derived Dendritic Cells

Immunosuppressive Drugs Upregulate the Immunoinhibitory Receptor Osteoactivin in Monocyte-Derived Dendritic Cells,

Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells

Quantitative Proteomic Profiling Unravels Dynamic Changes in the Myeloma Cell Proteome Treated with Valproic Acid (VPA)

Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-β on the cell surface

Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma

The Immune-Inhibitory Receptor Osteoactivin Is up-Regulated In Monocyte-Derived Dendritic Cells Upon Exposure to Tyrosine Kinase Inhibitors

Mutual Activation and Expansion of Donor CD4 + T Cells and B Cells in Transplants Play a Critical Role in the Initiation of Chronic Graft-Versus-Host Disease.

Integrin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.

Increased Immunohistochemical CD138 Expression in Waldenström's Macroglobulinemia (WM) in Comparison with Splenic Marginal Zone Lymphoma (SMZL).

Binding of TACI and APRIL to Syndecan-1 Confer on Them a Major Role in Multiple Myeloma.

BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.

Pleiotrophin Promotes Myeloma Proliferation through the Activation of Known and Novel Receptors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only